News and analysis on disease research and diagnostics.
Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.
Though the firm's total revenues were down year over year, its product and service revenue soared on sales of its ConfirmMDx Prostate cancer assay.
The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.
The development is a positive for plaintiff Amy Williams, who has said she hopes her lawsuit will spur greater accountability and transparency among genetic testing labs.
A team saw resilience and recolonization roles for antibiotic resistance gene-carrying microbes in the gut microbiomes of men treated with broad-spectrum antibiotics.
